News
LSTA
3.530
+4.75%
0.160
Weekly Report: what happened at LSTA last week (0610-0614)?
Weekly Report · 6d ago
Positive Outlook for Lisata Therapeutics Backed by Clinical Progress and Strategic Partnerships
TipRanks · 06/13 16:25
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Barinthus Biotherapeutics (BRNS)
TipRanks · 06/13 16:20
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Lisata Therapeutics (LSTA)
TipRanks · 06/13 16:10
Analysts Conflicted on These Healthcare Names: Incyte (INCY) and Lisata Therapeutics (LSTA)
TipRanks · 06/13 16:01
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Repligen (RGEN)
TipRanks · 06/13 15:51
Lisata Therapeutics Completes Full Enrollment Of Pancreatic Cancer Cohort Of CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. Of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers. Lisata Therapeutics completes successful completion of patient enrollment for the pancreatic cancer cohort in the CENDIFOX trial.
Benzinga · 06/13 12:36
LISATA THERAPEUTICS ANNOUNCES FULL ENROLLMENT OF PANCREATIC CANCER COHORT OF CENDIFOX TRIAL
Reuters · 06/13 12:30
Weekly Report: what happened at LSTA last week (0603-0607)?
Weekly Report · 06/10 10:32
Weekly Report: what happened at LSTA last week (0527-0531)?
Weekly Report · 06/03 10:34
Weekly Report: what happened at LSTA last week (0520-0524)?
Weekly Report · 05/27 10:37
Lisata Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 05/21 11:09
Buy Rating on Lisata Therapeutics Backed by Regulatory Milestones and Promising Study Progress
TipRanks · 05/21 10:25
Health Care Sector Update for 05/20/2024: ENSC, LSTA, HIMS, NKGN, NVO, LLY
NASDAQ · 05/20 19:58
EMa Grants Lisata Therapeutics Paediatric Investigation Plan Waiver For Certepetide In Pancreatic Cancer
Benzinga · 05/20 12:31
LISATA THERAPEUTICS RECEIVES PAEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY FOR CERTEPETIDE IN PANCREATIC CANCER
Reuters · 05/20 12:30
LISATA THERAPEUTICS INC - WAIVER CONFIRMS THAT PAEDIATRIC STUDIES OF CERTEPETIDE IN PANCREATIC CANCER ARE NOT NEEDED
Reuters · 05/20 12:30
Weekly Report: what happened at LSTA last week (0513-0517)?
Weekly Report · 05/20 10:32
Weekly Report: what happened at LSTA last week (0506-0510)?
Weekly Report · 05/13 10:39
Lisata Therapeutics, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 13:52
More
Webull provides a variety of real-time LSTA stock news. You can receive the latest news about Lisata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.